PERKINELMER AND BIOIMAGE ANNOUNCE COLLABORATION FOR CELL-BASED SCREENING APPLICATIONS
PERKINELMER AND BIOIMAGE ANNOUNCE COLLABORATION FOR CELL-BASED SCREENING APPLICATIONS
PerkinElmer Inc. a leading provider of drug discovery, life science research, and analytical solutions, announced plans to collaborate with BioImage to develop cell-based assays on the PerkinElmer EnVision™ HTS multilabel plate reader platform. The commercial terms of the collaboration were not disclosed. Based in Denmark, BioImage is a leader in using protein translocation based technology to identify novel therapeutics.
The collaboration combines the BioImage assay technology with the PerkinElmer EnVision detection platform to develop a series of cell based screening methods. BioImage has developed a suite of assay technologies for measuring protein-protein interactions in living cells using PerkinElmer’s EnVision platform. The EnVision provides extremely sensitive fluorometric detection at high speeds, making it the ideal detection platform for the BioImage assays. This powerful combination enables customers to perform robust cell based identification of inhibitors of protein/protein interactions at throughput levels previously not available.
“As a leader in high-content screening and cell-based assay development, BioImage has an excellent skill base and holds a strong IP position in this space,” said Peter Coggins, Ph.D., president, PerkinElmer Life and Analytical Sciences.
“This agreement provides a logical avenue for us to commercialize some of our technologies and collaborate with the leading provider of plate readers in the HTS market,” said Dr. Patrik Dahlén, CEO of BioImage. “We are actively out-licensing our IP estate and marketing our assay development services, and are confident that the assays validated on the EnVision platform will be of great interest to many bio-pharmaceutical companies.”
For more information, contact:
PerkinElmer Life and Analytical Sciences
549 Albany Street, Boston, MA, 02118, USA
Telephone: (800) 762-4000 (U.S. Only) or +1 (617) 482-9595
Fax: +1 (617) 482-1380
Website: www.perkinelmer.com/lifesciences .
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to cyclical downturns affecting several of the industries into which we sell our products, our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, risks related to our international operations, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption “Forward-Looking Information and Factors Affecting Future Performance” in our most recently filed annual report on Form 10-K and in our most recently filed quarterly report on Form 10-Q. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader focused in the following businesses – Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers’ needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
About BioImage
BioImage A/S is a drug discovery company based in Copenhagen focusing on cell-based pathway screening for the identification of new therapeutics. The Company has drug discovery projects in Inflammation and Oncology disease areas. BioImage’s approach to drug discovery monitors protein translocation in living cells as the primary assay readout. BioImage tracks protein translocation with relevant targets that are tagged with Green Fluorescent Protein (GFP), this allows BioImage to optimize the use of GFP to develop unique drug discovery screening technology.
BioImage employs approximately 40 people at its research facility in Copenhagen, Denmark. The company is financially backed by leading international investors including Apax Partners, Abingworth Management Ltd. ad Novo A/S. For more information please visit www.bioimage.com .
